NCT06006780

Brief Summary

Aim: The aim of this randomized clinical trial is to evaluate the use of the porcine acellular dermal matrix (PADM) for the treatment of RT1 localized gingival recessions. Material and methods: Forthy patients (n=20) with RT1 localized gingival recessions with height ranging from 3 to 5 mm with and at least, 2mm of keratinized tissue width will be selected to participate in the study. Patients will be allocated randomly in two treatment groups: Coronally advanced flap (CAF) or coronally advanced flap associated with the porcine acellular dermal matrix (CAF+ PADM). The clinical parameters evaluated at the baseline, 6 and 12 months will be: Plaque index (IPL); gingival index (GI); relative gingival recession height (RGRH); gingival recession width (GRW); probing depth (PD); relative clinical attachment level (RCAL); keratinized tissue height (KTH); keratinized tissue thickness (KTT); papilla height (PH). Evaluations will be made by the professional and the patient regarding dentin hypersensitivity (HD) (Schiff and VAS scales respectively), aesthetics (RES and VAS scales, respectively) and patient\'s centered outcomes, through the questionnaire referring to the OHIP-14. Descriptive statistical analysis will be expressed as mean ± standard deviation (SD), median, quartiles, percentages and confidence intervals (95% CI). To analyze the normality of the residue, the Shapiro-Wilk test will be performed. Then, the Wilcoxon test will be applied to compare the periodontal parameters and a quality of life, before and post-treatment. Correlations between parameters and dental hypersensitivity will be analyzed through Spearman\'s test. Key words: Gingival recession, Root coverage, Biomaterial, Acellular dermal matrix.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 10, 2022

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

August 17, 2023

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 23, 2023

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

April 2, 2025

Status Verified

March 1, 2025

Enrollment Period

2.3 years

First QC Date

August 17, 2023

Last Update Submit

March 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Recession change

    Change of the gingival recession height

    Baseline, 6 months and 12 months

Secondary Outcomes (1)

  • Thickness of keratinized tissue

    Baseline, 6 months and 12 months

Study Arms (2)

Coronally advanced flap (CAF)

ACTIVE COMPARATOR
Other: Coronally advanced flap (CAF)

Coronally advanced flap associated with the porcine acellular dermal matrix (CAF+ PADM)

EXPERIMENTAL
Device: Porcine acellular dermal matrix

Interventions

Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage

Also known as: Mucoderm
Coronally advanced flap associated with the porcine acellular dermal matrix (CAF+ PADM)

Coronally advanced flap for root coverage

Coronally advanced flap (CAF)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • RT1 localized gingival recessions with height ranging from 3 to 5 mm;
  • mm or more of keratinized tissue width ;
  • Probing depth less than 3mm;
  • Plaque and gingival index less or equal to 20%.

You may not qualify if:

  • Smokers;
  • Pregnants;
  • Nursing;
  • Patients with diabetes mellitus or another condition that interfere in the tissue repair
  • Patients who use drugs or medications that interfere in the tissue repair;
  • Allergies to any composition of the devices of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Piracicaba Dental School, State University of Campinas

Piracicaba, São Paulo, 13414-903, Brazil

Location

Related Publications (1)

  • Sangiorgio JPM, Neves FLDS, Rocha Dos Santos M, Franca-Grohmann IL, Casarin RCV, Casati MZ, Santamaria MP, Sallum EA. Xenogenous Collagen Matrix and/or Enamel Matrix Derivative for Treatment of Localized Gingival Recessions: A Randomized Clinical Trial. Part I: Clinical Outcomes. J Periodontol. 2017 Dec;88(12):1309-1318. doi: 10.1902/jop.2017.170126. Epub 2017 Jul 28.

    PMID: 28753100BACKGROUND

MeSH Terms

Conditions

Gingival Recession

Condition Hierarchy (Ancestors)

Gingival DiseasesPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesPeriodontal Atrophy

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, Chair of Periodontolgy Area

Study Record Dates

First Submitted

August 17, 2023

First Posted

August 23, 2023

Study Start

September 10, 2022

Primary Completion

December 30, 2024

Study Completion

December 30, 2024

Last Updated

April 2, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations